United States

VenatoRx Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Prior...

Lead Product(s): Non-beta-lactam antibiotic

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: NIAID

Deal Size: $44.2 million Upfront Cash: Undisclosed

Deal Type: Funding July 27, 2020

Details:

Funding aims to advance a novel series of Penicillin Binding Protein (PBP) Inhibitors targeting multi-drug resistant (MDR) Acinetobacter baumannii through Phase 1 clinical testing.

Hackensack Meridian CDI

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Hackensack Meridian Partners with Merck for Covid-19 Research

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 14, 2020

Details:

Hackensack Meridian CDI and Merck will work to discover drug candidates that can help treat Covid-19. Hackensack Meridian CDI will combine its expertise in academic drug discovery and viral pathogens analysis with Merck’s capabilities to discover and develop anti-infectives.

Dewpoint Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: $305.0 million

Deal Type: Collaboration July 13, 2020

Details:

Merck will apply Dewpoint’s proprietary platform for condensate-based drug discovery for the development of a novel mechanism to treat HIV.

Immunomic Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Replicate Bioscience and Immunomic Therapeutics Form Collaboration

Lead Product(s): RBI-5000

Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-5000

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Replicate Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 24, 2020

Details:

ITI and Replicate will develop candidates combining ITI’s UNITE technology with Replicate’s scalable self-replicating RNA (SynRGY technology) for COVID-19, HPV, and EBV.

Codiak BioSciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC™ Vaccine Platform in SARS-CoV-2 and HIV

Lead Product(s): exoVACC

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Ragon Institute

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 01, 2020

Details:

As part of the collaboration, Codiak researchers will work with Bruce Walker and Gaurav Gaiha of the Ragon Institute to build integrated exosome-based vaccines aimed at inducing broad neutralizing antibody and antigen-specific T cell protection against the viruses.

Twist Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection

Lead Product(s): Neutralizing antibody therapy

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Proteona

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

The international alliance was initiated by Proteona in response to the urgent need of patients most at risk facing the pandemic. The alliance aims to develop antibody therapies to provide a safe and targeted treatment for these vulnerable populations.

Shionogi Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Shionogi to Develop Prophylactic Vaccine for COVID-19

Lead Product(s): Prophylactic recombinant protein vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

In a project supported by the Japan Agency for Medical Research and Development (AMED), Shionogi and its subsidiary, UMN Pharma, are pursuing the discovery and development of a recombinant protein vaccine for COVID-19, using their unique technology.

Abcore

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Abcore Announces a Panel of Patent Pending Functional Single Domain Antibodies for Use as Therapeutic Candidates for Treatment of COVID-19

Lead Product(s): Single domain antibodies

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Abcore has demonstrated these therapeutic candidates bind to the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and functionally block binding to the Angiotensin Converting Enzyme-2 (ACE2) receptor.

IDBiologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19

Lead Product(s): Monoclonal antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Vanderbilt University Medical Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

For assessment and future licensing and clinical development, certain monoclonal antibodies discovered in Dr. James Crowe's laboratory at the Vanderbilt Vaccine Center will be shared with IDBiologics.

Atreca

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19

Lead Product(s): IgM antibodies

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: BeiGene

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 29, 2020

Details:

The companies will leverage their combined technology in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

VenatoRx Pharmaceuticals

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Prior...

Hackensack Meridian CDI

Hackensack Meridian Partners with Merck for Covid-19 Research

Dewpoint Therapeutics

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

Immunomic Therapeutics

Replicate Bioscience and Immunomic Therapeutics Form Collaboration

Codiak BioSciences

Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC™ Vaccine Platform in SARS-CoV-2 and HIV

Twist Bioscience

Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection

Shionogi Inc

Shionogi to Develop Prophylactic Vaccine for COVID-19

Abcore

Abcore Announces a Panel of Patent Pending Functional Single Domain Antibodies for Use as Therapeutic Candidates for Treatment of COVID-19

IDBiologics

Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19

Atreca

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19